About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of Osteogenesis Imperfecta Tendon | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT06065111

Study of Osteogenesis Imperfecta Tendon

Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with f...

Lead sponsor: Université Catholique de Louvain•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Catherine Behets

CONTACT

+3227645245 [email protected]

Antoine Chretien

CONTACT

[email protected]

Sponsors

Lead Sponsor

Université Catholique de Louvain

Collaborators

Hopital Lariboisière
University Hospital, Lille
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

This project aims to study the damage of tendon and ligament in a cohort of patients suffering from osteogenesis imperfecta. The data collected will be put into perspective with those of our first experimental work on mice. They will also make it possible to complete the specific care of these patients. Indeed, during the anamnesis, particular attention will be paid to the description of tendon-ligament pain in order to propose the most effective treatment for this kind of disorder, mainly in physiotherapy. Prevention work will surely be necessary with patients and caregivers.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•to have an osteogenesis imperfecta

Exclusion Criteria

•none, since we want to study different types of osteogenesis imperfecta and consider the effect of age.

Related studies

RECRUITINGPhase 3

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

NCT07366086 · Osteogenesis Imperfecta

RECRUITINGPhase 2

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

NCT07062588 · Osteogenesis Imperfecta (OI)

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

NCT07412782 · Osteogenesis Imperfecta, Osteoporosis, and more

RECRUITINGPhase 4

Effects of Bisphosphonates on OI-Related Hearing Loss

NCT04152551 · Osteogenesis Imperfecta

Active Not Recruiting

Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708

NCT05317637 · Osteogenesis Imperfecta

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 3, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment130

Start dateSep 2023

Last updatedOct 3, 2023

Condition

Osteogenesis Imperfecta

Locations shown

Pole de Morphologie

Woluwe-Saint-Lambert, Brussels Capital

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions